Portalase 300 Carbon Dioxide Surgical Laser Gynecologic
510(k) K854470
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK854470 | Date7 Feb 1986 | StatusActive |
Recalls
No FDA recalls found in the data synced 6 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- Full name
- Portalase 300 Carbon Dioxide Surg Laser Gynecologi
- 510(k) Number
- FDA Product Code
- HHR
- Device Class
- Class II
- Regulation
- 21 CFR Part 884.4550
- Advisory Committee
- Obstetrics/Gynecology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 6 Oct 2026
The Portalase 300 is a continuous wave carbon dioxide surgical laser designed for use in gynecologic procedures. This device functions by emitting light energy to cut, destroy, or remove tissue during surgery.
This Class II medical device is regulated under FDA 510(k) clearance K854470. It is manufactured by Minnesota Laser Corp. and is classified under regulation number 884.4550.
Other devices from Minnesota Laser Corp.
Questions
AI-generated answers, 6 Oct 2026
What is the primary clinical use of the Portalase 300?
The Portalase 300 is a continuous wave carbon dioxide surgical laser specifically engineered for gynecologic surgical applications. It operates by emitting light energy to perform tissue cutting, destruction, or removal during procedures.
What is the regulatory status of the Portalase 300?
The Portalase 300 is classified as a Class II medical device and is regulated under FDA 510(k) clearance number K854470. It falls under regulation number 884.4550 within the Obstetrics and Gynecology medical specialty.
Who manufactures the Portalase 300 and how was it cleared for use?
The device is manufactured by Minnesota Laser Corp., based in Minneapolis, Minnesota. It was cleared for use following a traditional 510(k) submission process, receiving a decision of substantial equivalence in February 1986.